A new small volume holding chamber for asthmatic children: Comparison with Babyhaler® spacer

Authors: Voeurng, Vireak1; Andrieu, Véronique1; Bun, Hot2; Reynier, Jean-Pierre1; Dubus, Jean-Christophe3

Source: Pediatric Allergy and Immunology, Volume 17, Number 8, December 2006 , pp. 629-634(6)

Publisher: Blackwell Publishing

Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content

Abstract:

Voeurng V, Andrieu V, Bun H, Reynier J-P, Dubus J-C. A new small volume holding chamber for asthmatic children: Comparison with Babyhaler® spacer.

Pediatr Allergy Immunol 2006: 17: 629-634. © 2006 The Authors Journal compilation © 2006 Blackwell Munksgaard

When a new holding chamber for administrating inhaled medication is to be marketed, it needs to be compared with existing chambers with two questions in mind: is this chamber well accepted by patients and is there an in vitro equivalence? We compared the new small volume non-electrostatic valved holding chamber, usable with all pressurized metered-dose inhalers and equipped with a funny facemask, Vortex® (Pari GmbH, Germany), to the most frequently prescribed holding chamber in France, Babyhaler® (GlaxoSmithKline Laboratories). Preferences were studied for 75 families with a child no more than 4 yr old, using standard questionnaires. An in vitro study assessed the delivered dose and the particle size distribution of two HFA beclomethasone dipropionate pressurized metered dose inhalers (Becotide® 250 μg per dose and Nexxair® 100 μg per dose) by dose uniformity sample apparatus and cascade impactor according to the European Pharmacopoeia. Vortex® was preferred by 95% of the families because of its small size, its duck facemask, and its robust appearance. Among children able to give their opinion, 86% preferred Vortex® to Babyhaler®. In vitro, both holding chambers reduced the delivered dose of beclomethasone dipropionate and increased the quantity of particles smaller than 5 μm in diameter with both medications. A higher proportion of fine particles was obtained with Nexxair® than with Becotide® (p < 0.05) and with Vortex® than with Babyhaler® (p < 0.05). As expected, throat deposition is dramatically reduced for both drugs with both holding chambers. The in vitro difference in the particle size distribution of beclomethasone dipropionate with both holding chambers probably has no clinical influence.

Keywords: Andersen cascade impactor; fine particle dose; holding chamber; mass median aerodynamic diameter; particle size; uniformity of delivered dose; pressurized metered dose inhaler; study of preference

Document Type: Research article

DOI: 10.1111/j.1399-3038.2006.00457.x

Affiliations: 1: Laboratoire de Pharmacie Galénique Industrielle et Cosmétologie, Faculté de Pharmacie Marseille, 13385 Marseille Cedex 5, France 2: Laboratoire de Toxicocinétique et Pharmacocinétique (EA 3286). Faculté de Pharmacie Marseille, 13385 Marseille Cedex 5, France 3: Unité de Médecine Infantile. CHU Timone Enfants et EA 328- IFR 125, Faculté de Médecine Marseille, 13385 Marseille Cedex 5, France

The full text electronic article is available for purchase. You will be able to download the full text electronic article after payment.

$50.39 plus tax      Refund Policy

 

OR

Back to top

Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content
Share this item with others: These icons link to social bookmarking sites where readers can share and discover new web pages.
Page Help Click here for Page Help
Shopping cart
Tools
Sign in






Need to register?
Sign up here
Text size: A | A | A | A